Uso de salbutamol e dopagem esportiva: uma revisão de literatura
DOI:
https://doi.org/10.34119/bjhrv7n9-388Keywords:
doping, β agonistas, salbutamol, broncodilatador, desempenhoAbstract
Este estudo avaliou o impacto do uso do salbutamol, um broncodilatador, na melhora do desempenho esportivo e sua relação com o doping. A utilização de substâncias para melhorar o desempenho é uma prática antiga que evoluiu até as regulamentações atuais, principalmente pela WADA, que limitam o uso de drogas no esporte competitivo para proteger a integridade e a saúde dos atletas. Embora o uso terapêutico do salbutamol por inalação seja permitido em doses controladas, seu uso pode proporcionar vantagens ergogênicas, melhorando a capacidade aeróbica e retardando a fadiga, especialmente em esportes de resistência como ciclismo e atletismo. Estudos indicam que doses excessivas podem aumentar os níveis de lactato, a ventilação e a frequência cardíaca, mas também trazem riscos, como tremores e arritmias. O trabalho destaca que, apesar do salbutamol ser permitido com restrições, ultrapassar os limites de dosagem equivalentes ao doping levanta questões éticas e de equidade no esporte. Assim, esta revisão de literatura visou avaliar se o uso do salbutamol, dentro ou fora das diretrizes da WADA, influencia significativamente o desempenho físico, analisando seus efeitos positivos e adversos, além de discutir a importância de controles antidopagem eficazes para garantir a competição.
References
AJAY, K.; SINGH. Textbook of Nephro-Endocrinology. 2. ed. 2018.
ALLEN, H.; BACKHOUSE, S. H.; HULL, J. H.; PRICE, O. J. Anti-doping policy, therapeutic use exemption and medication use in athletes with asthma: a narrative review and critical appraisal of current regulations. Sports Medicine, v. 49, n. 5, p. 659-668, maio 2019. doi: 10.1007/s40279-019-01075-z.
ANDERSEN, L. B, et al. All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. Archives of Internal Medicine, v. 160, p. 1621-1628, 2000.
ANDERSON, S. D.; KIPPELEN, P. Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes. The Journal of Allergy and Clinical Immunology, v. 122, n. 2, p. 225–237, 2008. Disponível em: https://doi.org/10.1016/j.jaci.2008.05.001. Acesso em: 7 out. 2024.
ANDERSON, S. D.; KIPPELEN, P. Exercise-induced bronchoconstriction: pathogenesis. Current Allergy and Asthma Reports, v. 5, n. 2, p. 116-122, mar. 2005. doi: 10.1007/s11882-005-0084-y.
ARTIOLI; et al. A. Terapia gênica, doping genético e esporte: fundamentação e implicações para o futuro. Revista Brasileira de Medicina do Esporte, Rio de Janeiro, p. 317-321, 2007.
AUCHUS, R. J. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinology and Metabolism Clinics of North America, v. 30, p. 101-119, 2001.
BACKHOUSE, S. H.; WHITAKER, L.; PETRÓCZI, A. Supplements, doping, and sport. Scandinavian Journal of Medicine & Science in Sports, v. 23, p. 244-252, 2013.
BAHRKE, M. S. Performance-enhancing substance misuse in sport: risk factors and considerations for success and failure in intervention programs. Substance Use & Misuse, v. 47, p. 1505-1516, 2012.
BARROSO, O.; MAZZONI, I.; RABIN, O. Hormone abuse in sports: the antidoping perspective. Asian Journal of Andrology, v. 10, p. 391-402, 2008.
BAUMAN, Zygmunt. O Mal-estar da Pós-Modernidade. Rio de Janeiro: Zahar, 1997.
Belle, D. J., & Singh, H. (2008). Genetic factors in drug metabolism. American family physician.
BELLE, D. J., & SINGH, H. (2008). Genetic factors in drug metabolism. American family physician.
BELLOTTI, P. Sport e bioetica: il potenziamento farmacologico e tecnologico dell’atleta. In: THAM, J.; LOSITO, M. (a cura di), Bioetica al futuro: Tecnicizzare l’uomo o umanizzare la tecnica? Città del Vaticano: Libreria Editrice Vaticana, 2010.
Bizjak DA et al. Acute Effects of Single Versus Combined Inhaled β2-Agonists Salbutamol and Formoterol on Time Trial Performance, Lung Function, Metabolic and Endocrine Variables. Sports Med Open. 2023 Aug 28;9(1):79. doi: 10.1186/s40798-023-00630-3. PMID: 37640958; PMCID: PMC10462601.
BLASCHKE T. Farmacocinética: Absorção, Distribuição, Metabolismo, Excreção Visão geral Capítulo. Em: Altman RB, Flockhart D, Goldstein DB, eds. Princípios de Farmacogenética e Farmacogenômica. Cambridge University Press.
BOGHOSIAN, T.; MAZZONI, I.; BARROSO, O.; RABIN, O. Investigating the use of stimulants in out-of-competition sport samples. Journal of Analytical Toxicology, v. 35, p. 613-616, 2011.
BOURDIEU, Pierre. A Distinção: Crítica Social do Julgamento. São Paulo: Zouk, 1979.
BRAGHIROLLI, et al..Farmacologia Aplicada. 1. ed. Ponta Grossa: Atena Editora, 2018.
CLERET, L. The role of anti-doping education in delivering WADA's mission. International Journal of Sport Policy and Politics, v. 3, p. 271-277, 2011.
COELHO, M. M. Doping genético, a atleta superior e bioética. Centro Universitário São Camilo, p. 171-180, 2012.
Courlet P, et al. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):469-481. doi: 10.1002/psp4.12773. Epub 2022 Mar 22. PMID: 35315251; PMCID: PMC9007606.
DE ROSE, E. H. Doping in athletes--an update. Clinics in Sports Medicine, v. 27, p. 1-30, 2008.
DICKINSON, J.; MOLPHY, J.; CHESTER, N.; et al. The ergogenic effect of long-term use of high dose salbutamol. Clinical Journal of Sport Medicine, v. 24, p. 474-481, 2014.
FILIPP, F. Is science killing the sport? gene therapy and its possible abuse in doping. European Molecular Biology Organization, v. 8, p. 433-435, 2007.
FITCH, K. D. An overview of asthma and airway hyper-responsiveness in Olympic athletes. British Journal of Sports Medicine, v. 46, n. 6, p. 413-416, 2012. doi: https://doi.org/10.1136/bjsports-2011-090814.
GOUBAULT C, PERAULT M, LELEU E. Effects of inhaled salbutamol in exercising non-asthmatic athletes Thorax 2001.
GRABER, S. E.; KRANTZ, S. B. Erythropoietin: biology and clinical use. Hematology/Oncology Clinics of North America, v. 3, n. 3, p. 369-400, 1989.
GUSTAFSSON, C. M.; MYERS, L. C.; BEVE, J.; et al. Identification of new mediator subunits in the RNA polymerase II holoenzyme from Saccharomyces cerevisiae. Journal of Biological Chemistry, v. 273, p. 7894-7899, 1998.
HABIB, G. et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, v. 36, p. 3075-3128, 2015.
HAISMA, H. J.; DE HON, O. Gene doping. International Journal of Sports Medicine, v. 27, p. 257-266, 2006.
HANDELSMAN, D. J. Performance enhancing hormone doping in sport. Endotext. South Dartmouth: MDText.com, 2000.
HOD, H.; HAR-ZAHAV, J.; KAPLINSKY, N.; FRANKL, O. Pindolol-induced tremor. Postgraduate Medical Journal, v. 56, p. 346-347, 1980.
HOSTRUP, M.; et al. Effects of acute and 2-week administration of oral salbutamol on exercise performance and muscle strength in athletes. Scandinavian Journal of Medicine & Science in Sports, v. 26, n. 1, p. 8–16, 2016. Disponível em: https://doi.org/10.1111/sms.12298. Acesso em: 7 out. 2024.
HUARD, J.; LI, Y.; PENG, H.; FU, F. Gene therapy and tissue engineering for sports medicine. Journal of Gene Medicine, v. 5, p. 93-108, 2003.
IMIR G Metushi et al. Breaking Boundaries: Exploring Performance Enhancement and Anti-Doping Testing in Sports, Clinical Chemistry, July 2024.
INSTITUTO PORTUGUÊS DO DESPORTO E JUVENTUDE (IPDJ). 2004.
JELKMANN, W.; LUNDBY, C. Blood doping and its detection. Blood, v. 118, n. 9, p. 2395-2404, 2011. doi: https://doi.org/10.1182/blood-2011-02-303271.
JOHNSON, M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr Respir Rev., v. 2, n. 1, p. 57-62, 2001. doi: 10.1053/prrv.2000.0102. PMID: 16263481.
KAMBER, M.; MULLIS, P. E. The worldwide fight against doping: from the beginning to the World Anti-Doping Agency. Endocrinol Metab Clin North Am, v. 39, p. 1-9, 2010.
KANAYAMA, G.; HUDSON, J. I.; POPE, H. G. Features of men with anabolic-androgenic steroid dependence: A comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend., v. 102, n. 1-3, p. 130-137, 2009. doi: 10.1016/j.drugalcdep.2009.02.008. PMID: 19339124; PMCID: PMC2694450.
KARTHIKEYAN, M. et al. Induction of phenolics and defense-related enzymes in coconut (Cocos nucifera L.) roots treated with biocontrol agents. Brazilian Journal of Plant Physiology, v. 18, n. 2, p. 367-377, 2006.
KASPER, D. et al. Nondetection of Helium in the Upper Atmospheres of Three Sub-Neptune Exoplanets. The American Astronomical Society, 2020.
KENNEDY, B. K. et al. Redistribution of silencing proteins from telomeres to the nucleolus is associated with extension of life span in S. cerevisiae. Cell, v. 89, n. 3, p. 381-391, 1997.
KINDERMANN, W. Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes? Sports Medicine (Auckland, N.Z.), v. 37, n. 2, p. 95–102, 2007. Disponível em: https://doi.org/10.2165/00007256-200737020-00001. Acesso em: 7 out. 2024.
KOLLER, W. et al. Pindolol-induced tremor. Clin Neuropharmacol., v. 10, n. 5, p. 449-452, 1987.
LIPPI, G.; FRANCHINI, M.; FAVALORO, E. J. Thrombotic complications of erythropoiesis-stimulating agents. Seminars in Thrombosis and Hemostasis, v. 36, n. 5, p. 537-549, 2010.
LIPPI, G.; GUIDI, G. Doping e sport. Minerva Medica, v. 90, n. 4, p. 345-357, 1999.
LIPPI, G.; GUIDI, G. Doping in Competition or Doping in Sport? British Medical Bulletin, v. 86, p. 95-107, 2008.
LOLAND, S. The exercise pill: should we replace exercise with pharmaceutical means? Sport, Ethics and Philosophy, v. 11, p. 63-74, 2017.
LORENTE, F. O.; PERETTI-WATEL, P.; GRELOT, L. Cannabis use to enhance sportive and non-sportive performances among French sport students. Addictive Behaviors, v. 30, n. 7, p. 1382-1391, 2005.
LUNDBY, C.; OLSEN, N. V. Effects of recombinant human erythropoietin in normal humans. Journal of Physiology, v. 589, p. 1265-1271, 2011. doi: 10.1113/jphysiol.2010.195917.
MACAULEY, D. Drugs in sport. British Medical Journal, v. 313, n. 7054, p. 463-465, 1996.
MARQUES, L.; VALE, N. Salbutamol in the Management of Asthma: A Review. International Journal of Molecular Sciences, v. 23, n. 22, p. 14207, 2022. Disponível em: https://doi.org/10.3390/ijms232214207. Acesso em: 7 out. 2024.
MEEUWISSE, W. H. et al. The effect of salbutamol on performance in elite nonasthmatic athletes. Medicine & Science in Sports & Exercise, v. 24, n. 10, p. 1161-1166, 1992.
Melo J., et al. Efeito agudo do salbutamol no sistema cardiovascular durante o exercício físico em pacientes com asma moderada ou grave: estudo aleatorizado, duplo-cego e cruzado. 2018. https://doi.org/10.1590/1809-2950/17007725022018
MOLPHY, J. et al. The Effect of 400 µg Inhaled Salbutamol on 3 km Time Trial Performance in a Low Humidity Environment. Journal of Sports Science & Medicine, v. 16, n. 4, p. 581-588, 2017.
MUDRAK, J. et al. Occupational well-being among university faculty: A job demands-resources model. Research in Higher Education, v. 59, n. 3, p. 325-348, 2018.
NETO, F. R. A. O papel do atleta na sociedade e o controle de dopagem no esporte. Revista Brasileira de Medicina do Esporte, v. 7, n. 4, p. 171-180, 2001.
O uso do doping sanguíneo como recurso ergogênico. Revista Brasileira de Medicina do Esporte, v. 5, n. 5, p. 194-201, 1999.
PALMI, I. et al. The unethicality of doping in sports. La Clinica Terapeutica, v. 170, n. 2, p. 100-101, 2019.
PLUIM, B. M. et al. β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials. Sports Med., v. 41, n. 1, p. 39-57, 2011. doi: 10.2165/11537540-000000000-00000.
ROSKOSKI JR, R. Bioquímica. Rio de Janeiro: Editora Guanabara Koogan, 1997.
RUBANYI, G. M. The future of human gene therapy. Molecular Aspects of Medicine, v. 22, p. 113-142, 2001.
SCHUMACHER, Y. O. et al. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. Drug Test Anal., 2010.
SPRIET, L. L. Blood doping and oxygen transport. In: LAMB, D. R.; WILLIAMS, M. H. Ergogenics: enhancement of performance in exercise and sport. Indianapolis: William C. Brown & Benchmark, 1991. p. 213-248.
STAUCH, B. J. et al. Stimulus-specific plasticity in human visual gamma-band activity and functional connectivity. Elife, v. 10, p. 63-74, 2021.
TRIPI, F. et al. Education to legality and doping. Annali di Igiene: Medicina Preventiva e di Comunita, v. 31, n. 2, p. 100-101, 2019.
VLAD, R. A. et al. Doping in Sports, a Never-Ending Story? Advances in Pharmaceutical Bulletin, v. 8, n. 1, p. 1-10, 2018.
WADLER, G. I.; HAINLINE, B. Drugs and the athlete. Philadelphia: FA Davis Company, 1989.
WILSON, T. D. Strangers to ourselves: Discovering the adaptive unconscious. Cambridge: Harvard University Press, 2002.
WONG, K. C. et al. The adverse effects of recombinant human erythropoietin therapy. Advances in Drug Reactions and Acute Poisoning Reviews, v. 9, p. 183-206, 1990.
WORLD ANTI DOPING AGENCY. Salbutamol Data. Disponível em: https://www.wada-ama.org/en/resources/scientific-research/salbutamol-data.
WORLD ANTI-DOPING AGENCY. Código Mundial Antidopagem. Montreal: World Anti-Doping Agency, 2015.
WORLD ANTI-DOPING AGENCY. Prohibited List. Montreal: World Anti-Doping Agency, 2011.
